Abstract:Purpose/Objective(s)To prospectively explore the clinical and functional outcomes of chemoradiation therapy for locally advanced nasopharyngeal carcinoma (NPC), using intensity-modulated radiation therapy (IMRT) to spare the salivary glands and related swallowing structures to reduce xerostomia and dysphagia.Materials/MethodsPatients with locally advanced and treatment naive NPC (stage III, IVa, and IVb) were enrolled into this study. Treatment protocol was curative IMRT combined with weekly chemotherapy (cisplatin 40 mg/m2). The medial group retropharyngeal nodes were never contoured as CTV aiming to spare the pharyngeal constrictors unless they were involved. Level Ib node was selectively contoured as CTV in order to spare the submandibular glands and oral cavity. Dose prescriptions were GTV 66-70.4 Gy/30-32 Fx, CTV1 60 Gy/30-32 Fx, and CTV2 54-56 Gy/30-32 Fx. Swallowing and salivary glands function were evaluated by patient-reported, observer-rated scores before therapy and periodically after treatment through 3years.ResultsFrom January 2008 to January 2010, 310 patients with stages III to IVb NPC were recruited into this study. With a median follow-up of 39 months, the 3-year local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastases-free survival (DMFS) were 93.6%, 95.8%, and 80%, respectively. There were no out-of-field or marginal relapse. Dysphagia and xerostomia worsened during the late course of radiation therapy and after treatment. But observer-rated and patient-reported scores recovered gradually over time 3 months after therapy. At 9 months after radiation therapy, both patient-reported and observer-rated dysphagia were absent or minimal, and this situation continued until the last follow-up. Patient-reported scores showed that xerostomia began to improve from 3 to 15 months after radiation therapy, and then became steady until the last follow-up.ConclusionsIMRT concurrent with weekly chemotherapy aiming to reduce xerostomia and dysphagia can be safely performed for locally advanced NPC and has high locoregional control rates. Distant metastasis remains the main failure pattern. Long-term patient-reported and observer-rated swallowing and salivary glands function were only slightly worse than baseline. Purpose/Objective(s)To prospectively explore the clinical and functional outcomes of chemoradiation therapy for locally advanced nasopharyngeal carcinoma (NPC), using intensity-modulated radiation therapy (IMRT) to spare the salivary glands and related swallowing structures to reduce xerostomia and dysphagia. To prospectively explore the clinical and functional outcomes of chemoradiation therapy for locally advanced nasopharyngeal carcinoma (NPC), using intensity-modulated radiation therapy (IMRT) to spare the salivary glands and related swallowing structures to reduce xerostomia and dysphagia. Materials/MethodsPatients with locally advanced and treatment naive NPC (stage III, IVa, and IVb) were enrolled into this study. Treatment protocol was curative IMRT combined with weekly chemotherapy (cisplatin 40 mg/m2). The medial group retropharyngeal nodes were never contoured as CTV aiming to spare the pharyngeal constrictors unless they were involved. Level Ib node was selectively contoured as CTV in order to spare the submandibular glands and oral cavity. Dose prescriptions were GTV 66-70.4 Gy/30-32 Fx, CTV1 60 Gy/30-32 Fx, and CTV2 54-56 Gy/30-32 Fx. Swallowing and salivary glands function were evaluated by patient-reported, observer-rated scores before therapy and periodically after treatment through 3years. Patients with locally advanced and treatment naive NPC (stage III, IVa, and IVb) were enrolled into this study. Treatment protocol was curative IMRT combined with weekly chemotherapy (cisplatin 40 mg/m2). The medial group retropharyngeal nodes were never contoured as CTV aiming to spare the pharyngeal constrictors unless they were involved. Level Ib node was selectively contoured as CTV in order to spare the submandibular glands and oral cavity. Dose prescriptions were GTV 66-70.4 Gy/30-32 Fx, CTV1 60 Gy/30-32 Fx, and CTV2 54-56 Gy/30-32 Fx. Swallowing and salivary glands function were evaluated by patient-reported, observer-rated scores before therapy and periodically after treatment through 3years. ResultsFrom January 2008 to January 2010, 310 patients with stages III to IVb NPC were recruited into this study. With a median follow-up of 39 months, the 3-year local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastases-free survival (DMFS) were 93.6%, 95.8%, and 80%, respectively. There were no out-of-field or marginal relapse. Dysphagia and xerostomia worsened during the late course of radiation therapy and after treatment. But observer-rated and patient-reported scores recovered gradually over time 3 months after therapy. At 9 months after radiation therapy, both patient-reported and observer-rated dysphagia were absent or minimal, and this situation continued until the last follow-up. Patient-reported scores showed that xerostomia began to improve from 3 to 15 months after radiation therapy, and then became steady until the last follow-up. From January 2008 to January 2010, 310 patients with stages III to IVb NPC were recruited into this study. With a median follow-up of 39 months, the 3-year local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastases-free survival (DMFS) were 93.6%, 95.8%, and 80%, respectively. There were no out-of-field or marginal relapse. Dysphagia and xerostomia worsened during the late course of radiation therapy and after treatment. But observer-rated and patient-reported scores recovered gradually over time 3 months after therapy. At 9 months after radiation therapy, both patient-reported and observer-rated dysphagia were absent or minimal, and this situation continued until the last follow-up. Patient-reported scores showed that xerostomia began to improve from 3 to 15 months after radiation therapy, and then became steady until the last follow-up. ConclusionsIMRT concurrent with weekly chemotherapy aiming to reduce xerostomia and dysphagia can be safely performed for locally advanced NPC and has high locoregional control rates. Distant metastasis remains the main failure pattern. Long-term patient-reported and observer-rated swallowing and salivary glands function were only slightly worse than baseline. IMRT concurrent with weekly chemotherapy aiming to reduce xerostomia and dysphagia can be safely performed for locally advanced NPC and has high locoregional control rates. Distant metastasis remains the main failure pattern. Long-term patient-reported and observer-rated swallowing and salivary glands function were only slightly worse than baseline.

Long-term follow-up of protective effects on salivary and swallowing structures and improvement of late xerostomia and dysphagia by level IIb optimisation in clinical target volume of nasopharyngeal carcinoma

Long-term results of phase II trial of reduced modified clinical target volume in low-risk nasopharyngeal carcinoma treated with intensity modulated radiotherapy

Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up

Reducing Target Volumes of Intensity Modulated Radiation Therapy After Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial

Reducing Target Volumes of Intensity-Modulated Radiotherapy Following Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial

Impact on xerostomia for patients with nasopharyngeal carcinoma treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study.

Long-term Efficacy and Adverse Effects of Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma

Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost

Long-term survival of nasopharyngeal carcinoma patients with Stage II in intensity-modulated radiation therapy era.

Long-Term Result of A Multicenter Clinical Study of Cetuximab Combined with Intensity Modulated Radiotherapy (imrt) Plus Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (Npc).

Selective Nodal Irradiation by Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma Aiming to Reduce Dysphagia and Xerostomia

A retrospective concurrent control study of induction chemotherapy in 104 patients with stage II nasopharyngeal carcinoma

Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study

Contralateral Lower Neck Sparing Radiotherapy in Stage N1 Nasopharyngeal Carcinoma: Long-Term Survival Outcomes and Late Toxicities

Corrigendum to "Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma" [Oral Oncol. 73 (2017) 118-123]

Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma

Long-term outcomes of nasopharyngeal carcinoma treated with helical tomotherapy using simultaneous integrated boost technique: A 10-year result

Long-term Results of the Phase II Dose and Volume De-Escalation Trial for Locoregionally Advanced Nasopharyngeal Carcinoma.

Long-term survival, toxicities, and the role of chrono-chemotherapy with different infusion rates in locally advanced nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy: a retrospective study with a 5-year follow-up

Comparing Long-Term Survival and Late Toxicities of Different Sequential Chemotherapy Regimens with Intensity-Modulated Radiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

A retrospective study of 606 cases of nasopharyngeal carcinoma with or without oropharyngeal candidiasis during radiotherapy